Relationship Between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a *Neisseria gonorrhoeae* Hollow-Fiber *In Vitro* Infection Model

Short title: Prevention of on-therapy gepotidacin resistance to GC

1Brian D. VanScoy, 2Nicole E. Scangarella-Oman, 1Steven Fikes, 2Sharon Min, 2Jianzhong Huang, 2Karen Ingraham, 1Sujata M. Bhavnani, 1Haley Conde, 1Paul G. Ambrose

1Institute for Clinical Pharmacodynamics, Inc., Schenectady, NY; 2GlaxoSmithKline, Collegeville, PA

Key Words: *Neisseria gonorrhoeae*, gepotidacin, pharmacokinetics-pharmacodynamics

*Corresponding Author:

Brian D. VanScoy, BS
Institute for Clinical Pharmacodynamics, Inc.
242 Broadway
Schenectady, NY 12305
Phone: (518) 631-8100
Fax: (518) 631-8199
Email: bvanscoy@icpd.com
ABSTRACT

Multi-drug resistant *Neisseria gonorrhoeae* has emerged as a threat to global health. The relationship between gepotidacin exposure and prevention of on-therapy amplification of drug-resistant *N. gonorrhoeae* was examined using a 7-day hollow-fiber *in vitro* infection model. The study design included both inactive (no-treatment and ciprofloxacin) and active (ceftriaxone) control regimens. Study drug concentration-time profiles were simulated in the *in vitro* system for a single oral 0.5 g ciprofloxacin dose, a single intramuscular 0.25 g ceftriaxone dose, and single or two (8-12 hours apart) oral gepotidacin doses ranging from 0.75 to 12 g. The initial bacterial burden inoculated in the model was $10^6$ CFU/mL. The study drug broth MIC to the challenge isolate (*N. gonorrhoeae* GSK #8) was gepotidacin-0.5 mg/L, ciprofloxacin-2 mg/L, and ceftriaxone-0.002 mg/L. Samples were collected for enumeration of total and drug-resistant bacterial populations and drug concentrations. The no-treatment control reached a bacterial density greater than $10^8$ CFU/mL over 24h and remained consistent over the 7-day study period. The bacterial density in the model system of the ciprofloxacin regimen matched that of the growth control throughout the study duration while the ceftriaxone regimen sterilized the model system by the end of Day 1. For gepotidacin, a full dose-response effect was observed. While failure was observed for the 0.75, 1.5, and 3 g single-dose regimens, all gepotidacin single- or divided-dose regimens totaling at least 4.5 g prevented resistance amplification and sterilized the model system. These data are useful to provide gepotidacin dose selection support for treating patients with gonorrhea infections.
INTRODUCTION

Gonorrhea is a common and often painful sexually transmitted disease caused by the bacterium, *Neisseria gonorrhoeae*. Gonorrhea is increasing in prevalence across many regions of the world, including America, Europe, and Asia [1, 2, 3, 4]. Worldwide, the World Health Organization estimates 78 million new cases of gonorrhea are acquired each year [5].

A major challenge in treating patients with gonorrhea is the emergence of multidrug-resistant *Neisseria gonorrhoeae* [6]. In a recent study, only 4.9% of isolates were fully drug-susceptible when tested against azithromycin, ceftriaxone, ciprofloxacin, gentamicin, penicillin, and tetracycline [7]. Alarmingly, 37.8% of these isolates were resistant to at least three of the tested antibiotics. There was great variability among antibiotic in vitro susceptibility rates, ranging from 13.1% for penicillin, and approaching 100% for ceftriaxone and azithromycin. Interestingly, these data suggest decreased susceptibility is more frequent with short rather than long half-life agents. The contribution of short half-life agents to the development of resistance may be the result of the use of a single-dose therapy strategy [8] for such agents when treating patients with gonorrhea.

Gepotidacin (GSK2140944) is a novel bacterial type II topoisomerase inhibitor, dual targeting bacterial DNA gyrase and topoisomerase IV by a different mechanism from the marketed fluoroquinolone antibiotics [9]. Gepotidacin has
in vitro activity against a wide array of bacterial species, including N. gonorrhoeae [10]. To support the selection of dosing regimens for the treatment of patients with uncomplicated urogenital infection caused by N. gonorrhoeae enrolled in a pivotal Phase 3 clinical study that is currently underway (ClinicalTrials.gov Identifier: NCT04010539), we conducted studies using a hollow-fiber in vitro infection model. The objective of these studies was to identify single- and multiple-dose gepotidacin exposures that would prevent the development of on-therapy resistance.
RESULTS

**In Vitro Susceptibility Testing.** The minimum inhibitory concentration (MIC) of each study drug against the five clinical *N. gonorrhoeae* isolates is presented in Table 1. The wild-type ATCC 49226 *N. gonorrhoeae* reference strain MIC value was within the expected range for all three challenge compounds [11]. Each of the five isolates were ceftriaxone-susceptible (MIC ≤0.25 mg/L) and ciprofloxacin-resistant (MIC ≥1 mg/L) when tested by agar dilution using gonococcal agar [12]. The gepotidacin MIC values ranged from 0.25 to 1 mg/L across the five isolates. MIC values across study drugs were similar when tested by agar dilution using gonococcal agar or by broth microdilution using fastidious liquid growth media.

**Resistance Frequency Assay.** The frequency of resistance to gepotidacin assay results are presented in Table 2. The frequencies of resistance to gepotidacin at 4x MIC were generally low (<1.5 x 10^{-8}) and there were no resistant isolates recovered for three out of the five isolates examined (GSK #2, #5, and #7). For the remaining two isolates (GSK #4 and #8), frequencies of resistance ranged from 8.0 x 10^{-8} to 9.1 x 10^{-5} at 2.5x the MIC value and gepotidacin resistance was virtually undetectable at 4x the MIC value. The gepotidacin MIC values for the two isolates collected from the gepotidacin-containing agar plates were each determined to be 16 mg/L, regardless of the gepotidacin concentration of the agar plate.
Pharmacokinetics. The agreement between observed and targeted study drug concentrations was high (gepotidacin: coefficient of determination ($r^2$) = 0.9733, slope = 0.9938, and intercept = 0.0153; ceftriaxone: $r^2$ = 0.9732, slope = 1.0406, and intercept = 0.0159; ciprofloxacin: $r^2$ = 0.9536, slope = 0.9316, and intercept = 0.0074), with $r^2$ indicating goodness of fit, and slope representing deviations of 1 ranging from 0.7 to 6.9% percent for the three challenge compounds. Figure 1A and Figure 1B show the targeted concentration time profile for gepotidacin, ceftriaxone, and ciprofloxacin in the hollow-fiber in vitro infection model, with observed data overlaid. These data indicated that each study drug was well-simulated in the hollow-fiber in vitro infection model.

Hollow-Fiber In Vitro Infection Model. Based on the results of the above-described resistance-frequency studies, N. gonorrhoeae GSK #8 met the criteria described in the methods section, and the results of hollow-fiber in vitro infection model studies based on data for this isolate are described below.

The change in the total and antibiotic-resistant bacterial subpopulations over time for the no-treatment, ceftriaxone 0.25 g IM, and ciprofloxacin 0.5 g oral (PO) control regimens based on data for N. gonorrhoeae GSK #8 are presented in Figure 2. The no-treatment control regimen grew well, achieving a bacterial density approaching 9-log$_{10}$ CFU/mL by Day 1 and maintaining a generally consistent ratio of the total- to the drug-resistant-subpopulations over the 7-day study period. Note, the ceftriaxone and ciprofloxacin control regimens performed
as expected given the baseline MIC values for *N. gonorrhoeae* GSK #8. The ciprofloxacin regimen failed (as evidenced by bacterial burdens greater than initial inocula at the end of the study duration) while success (i.e., reduction in CFU burden to undetectable levels) was observed for the ceftriaxone regimen.

The change in the total and antibiotic-resistant bacterial subpopulations over time for the gepotidacin regimens based on data for *N. gonorrhoeae* GSK #8 are presented in Figure 3. A full gepotidacin exposure-response was observed over the range of doses from 0.75 to 12 g PO, which represented AUC values of 16.2 to 278 mg•h/L. That is, low gepotidacin exposures resulted in regimen failure with drug-resistance amplification and high exposures resulted in the sterilization of the infection model. All gepotidacin single-dose regimens greater than or equal to 4.5 g prevented resistance amplification and sterilized the infection model over the seven day period. The 6 g gepotidacin dose, split into two equal doses administered at 0 and 8 or 12 hours, prevented resistance amplification and sterilized the infection model over the seven day period. As shown in Figure 4, the relationship between gepotidacin total dose and change in bacterial density from baseline of the gepotidacin-resistant subpopulation on Day 7 for *N. gonorrhoeae* GSK #8, isolated from plates containing gepotidacin concentrations at 2x MIC, took the form of an inverted-U-shape curve. The gepotidacin agar MIC values of isolates collected from the 2x MIC gepotidacin-containing plates ranged from 2 to 16 mg/L. A subset of these isolates tested against gepotidacin in the presence of a broad-spectrum efflux pump inhibitor
(phe-arg beta napthylamide dihydrochloride) demonstrated ≤2-fold decrease in MIC except for one isolate with an 8-fold decrease in MIC.

**Genotype Characterization.** Fifty-one *N. gonorrhoeae* isolates with gepotidacin agar MIC values ranging from 1 to 16 mg/L were recovered on gepotidacin-containing 4x MIC plates from the hollow-fiber *in vitro* infection model studies conducted using isolate GSK #8 (baseline gepotidacin agar MIC 1 mg/L). Aside from the following pre-existing substitutions that were also present in the parent isolate, GyrA S91F, D95A; ParC D86N, an additional GyrA A75S or A92T/V substitution was identified in all but two gepotidacin isolates recovered from the 1.5 and 3 gram gepotidacin treatment groups. The gepotidacin MIC was 16 mg/L (16-fold increase in MIC compared to parent isolate) for all except one isolate (MIC 2 mg/L). Isolates recovered from the 0.75 gram gepotidacin treatment group had a 4-fold increase in gepotidacin MIC (MIC 4 mg/L) compared to the parent isolate and were found to have a V36I substitution in GyrA.
DISCUSSION

The overarching goal of the studies described herein was to evaluate gepotidacin dosing regimens to support the dose selection for the pivotal Phase 3 clinical study. Specifically, we conducted hollow-fiber *in vitro* infection model studies to identify single- and multiple-dose gepotidacin exposures that would prevent the development of on-therapy resistance. Moreover, we sought to characterize gepotidacin-resistant isolates collected from drug-containing plates.

The relationship between gepotidacin exposure and drug resistance amplification based on data from the hollow-fiber *in vitro* infection took the form of an inverted-U-shape curve. More specifically, low single gepotidacin doses modestly amplified gepotidacin resistance, intermediate doses maximally amplified gepotidacin-resistant subpopulations, while higher doses prevented the amplification of gepotidacin-resistant subpopulations (*Figure 4*). Single 4.5 g gepotidacin doses or greater prevented the amplification of resistant subpopulations and sterilized the system by Day 7. Two gepotidacin 3 g doses administrated at 0 and 8 or 12 hours apart also prevented amplification of gepotidacin-resistant subpopulations and sterilized the system by Day 7.

Of the gepotidacin-resistant isolates recovered from the hollow-fiber *in vitro* infection model studies, there were a limited number of substitutions in GyrA (V36I, A75S, and A92T/V) identified. These results are consistent with both previously conducted *in vitro* resistance frequency assays and also clinical study...
results, where GyrA A92T (with a gepotidacin agar MIC increase ≥16-fold) was the only additional target-based mutation identified in the in vitro assay or in isolates recovered post-therapy from urogenital specimens for two subjects [13, 14]. In this study, it is likely that the additional GyrA substitutions (V36I, A75S, and A92T/V) contributed to the reduced gepotidacin susceptibility of these isolates, as the gepotidacin MIC values were unaffected by the addition of a broad-spectrum efflux pump inhibitor.

There are a number of strengths of the dynamic hollow-fiber in vitro infection model studies described herein relative to in vitro resistance frequency assays or other static PK-PD infection models including the extended study duration of 7 days. Although N. gonorrhoeae bacterial load can vary significantly for different patient body sites, the bacterial density achieved in this study was similar to larger bacterial burdens as described in the literature [15, 16, 17, 18]. Additionally, the expected performance of the inactive and active control regimens was easily demonstrated. That is, the no-treatment control regimen grew well, the ciprofloxacin regimen failed and the ceftriaxone regimen succeeded in the context of the challenge isolate that was resistant to ciprofloxacin and susceptible to ceftriaxone (Figure 2). Importantly, the gepotidacin-resistant isolates recovered from the hollow-fiber in vitro infection model studies contained target-site mutations consistent with those identified from two gepotidacin-treated patients with uncomplicated urogenital gonorrhea enrolled in a Phase 2 clinical study [13, 14]. The variable efficacy/resistance
amplification of the 3 g dose in the hollow-fiber infection model studies was also consistent with the results seen for this dose in the Phase 2 clinical study [13, 14]. Given these concordant findings, data from studies conducted using the hollow-fiber in vitro infection model described herein may be particularly useful to forecast effective regimens for the treatment uncomplicated urogenital gonorrhea.

There are a few limitations to the work described herein. First, only one isolate was evaluated in the hollow-fiber in vitro system, and as such we are unable to evaluate inter-isolate variability surrounding the exposure associated with resistance prevention. Second, only one initial bacterial inoculum was evaluated, and given the variability in bacterial burden associated with various infection sites, further work will need to be completed in order to explore the effect that the initial bacterial inoculum may have on gepotidacin activity. Third, the PK profiles simulated in the in vitro system represented free-drug plasma exposures rather than exposures at other potential effect sites such as the pharynx and thus, may not be reflective of other effect site exposures.

In conclusion, we conducted hollow-fiber in vitro infection model studies to identify single- and multiple-dose gepotidacin exposures that would prevent the development of on-therapy gepotidacin resistance. The gepotidacin-resistant isolates recovered from the hollow-fiber in vitro infection model studies contained additional GyrA mutations consistent with those identified from gepotidacin-
treated patients enrolled in a clinical study. These data can be used to support the selection of future gepotidacin dosing regimens for the treatment of patients with uncomplicated urogenital gonorrhea that minimize the potential for on-therapy drug-resistance amplification.
METHODS

**Bacteria and Antimicrobial Agents.** Six *N. gonorrhoeae* isolates were evaluated in the studies described herein. One (ATCC 49226) was purchased from the American Type Culture Collection (ATCC, Manassas, VA). The remaining five isolates were clinical isolates, each from a baseline culture obtained from gepotidacin-treated patients with uncomplicated urogenital gonorrhea enrolled in a Phase 2 dose-ranging study [13]. All five isolates contained a pre-existing ParC D86N mutation that likely conferred resistance to fluoroquinolones. However, this mutation compromised dual targeting by gepotidacin as ParC D86 is a critical residue for interacting with gepotidacin. Clinical resistance to gepotidacin likely developed from the subpopulation containing the preexisting ParC D86N mutation [14]. Gepotidacin was provided by GlaxoSmithKline while ciprofloxacin and ceftriaxone were each purchased from Henry-Schein Medical (Mellville, NY).

**In Vitro Susceptibility Testing.** MIC testing of each study drug was performed in triplicate by two methods over two days. Agar dilution testing using gonococcal agar (Remel San Diego, CA) was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines [11]. MIC values were also determined by microbroth dilution testing using fastidious broth (FB) media [19], as this liquid media was used in the hollow-fiber *in vitro* infection model studies described below.
Resistance Frequency Assay. Frequency of resistance to gepotidacin was determined for each of the five clinical isolates. A 5 mL sample was collected from a bacterial suspension in mid-log phase growth for each isolate. Next, 200 µL aliquots were inoculated onto 25 gonococcal agar plates supplemented with gepotidacin concentrations equal to 2.5x and 4x the gepotidacin agar MIC for each isolate. The inoculated agar plates were incubated in the presence of 5% CO₂ for a 72-hour period. Resistance frequency was determined as the ratio of the growth on the drug-containing agar plates (number of resistant isolates) to that of the starting inoculum. For those drug-containing plates with observable bacterial growth, a subset of isolates were taken for agar-based gepotidacin MIC determination and compared to that of baseline.

Hollow-Fiber In Vitro Infection Model. The hollow-fiber in vitro infection model used in these studies has been described previously [20, 21]. Briefly, the hollow-fiber in vitro infection model is a two-compartment in vitro pharmacokinetic-pharmacodynamic (PK-PD) system. The challenge isolate is maintained in a peripheral compartment, from which the organism cannot escape. With the aid of computer-controlled peristaltic pumps, study drug and fresh bacterial growth media is circulated through a central compartment into and out of the peripheral compartment. The pump rates can be set such that virtually any drug concentration-time profile can be simulated in the system. Hollow-fiber cartridge sampling ports allow for the determination of drug and bacteria concentrations over time.
Hollow-Fiber In Vitro Infection Model Studies. The isolate selection criteria for the hollow-fiber in vitro infection model included the following: 1) gepotidacin agar MIC < 2 mg/L; 2) gepotidacin resistance frequency greater than $1.0 \times 10^{-9}$ CFU/mL but less than $1.0 \times 10^{-7}$ (in order to select an isolate associated with a known resistant subpopulation); 3) ciprofloxacin-resistant and ceftriaxone-susceptible; and 4) having identical gepotidacin MIC values between the agar and broth methodologies. The inocula for the selected challenge isolate were prepared from overnight cultures on chocolate II agar (Becton, Dickinson and Company, Franklin Lakes, NJ) in the presence of 5% CO$_2$. Colonies from overnight cultures were grown to mid-log-phase, suspended in fastidious broth medium and the bacterial density confirmed by optical density using a previously derived bacterial growth curve. Finally, a bacterial suspension volume containing $1 \times 10^6$ CFU/mL was inoculated into each hollow-fiber cartridge's (FiberCell Systems, Frederick, Maryland) peripheral compartment in order to simulate a clinically relevant bacterial burden as described based on the literature [15, 16, 17, 18].

Three different study antibiotics were evaluated in the hollow-fiber in vitro infection models, ceftriaxone, ciprofloxacin, and gepotidacin. For all study antibiotics, free-drug concentration-time profiles were simulated in the hollow-fiber in vitro infection model. Ceftriaxone was infused into the system in a manner that mimicked the concentration-time profile in adult humans following a single 0.25 g intramuscular injection [22] and which represented a component of the
current Center for Disease Control (CDC)-recommended treatment regimen [23]. Ciprofloxacin was infused in the system in a manner that simulated the concentration-time profile in adult humans after a single 0.5 g PO dose [24] and which represented the former CDC recommended regimen [25]. Gepotidacin was administered in a manner that mimicked adult human concentration-time profiles following a single PO dose [26]. In order to fully characterize the exposure-response profile for gepotidacin, single PO doses ranged from 0.75 to 12 g [26]. In addition, a 6 g gepotidacin daily dose was evaluated as two equally divided doses administered either 8 or 12 hours apart. All hollow-fiber *in vitro* infection model studies were conducted in at least duplicate and over a 7 day period.

One milliliter samples were collected to determine drug bacterial density were collected from the hollow-fiber *in vitro* infection model immediately prior to study antibiotic administration, 4 hours post treatment initiation and on Study Days, 1, 2, 3, 5, and 7. To determine the effect of study antibiotic treatment on the total bacterial population, samples were washed twice using sterile normal saline, serially diluted, and quantitatively cultured on drug-free chocolate agar plates (Becton Dickson, Heidelberg, Germany). To enumerate the antibiotic-resistant subpopulation density, a portion of each bacterial sample was plated on chocolate agar supplemented with each study antibiotic at a concentration equal to 2x or 4x the baseline MIC. Finally, to investigate the effect of efflux, MIC values were determined with and without the presence of 40 mg/L phe-arg beta-naphthylamide dihydrochloride (Sigma-Aldrich) for each study day sampled.
Samples for drug concentration determination were collected from the hollow-fiber *in vitro* infection model at 1, 2, 4, 7, 10, 24, 27, 30, and 47 hours after treatment initiation. Samples were immediately frozen at \(-80^\circ\text{C}\) until assayed for drug concentration via liquid chromatography-tandem mass spectrometry.

**Genotype Characterization.** PCR amplification was performed on a subset of isolates collected from the resistance frequency and hollow-fiber *in vitro* infection model. The quinolone resistance determining regions (QRDR) which are “hot spots” for substitutions were analyzed. PCR products were separated, visualized, and sized by electrophoresis on a 1% agarose gel containing ethidium bromide, purified following manufacturer’s instructions using the PCR purification kit, and re-suspended in 30 μL sterile distilled H₂O. PCR products were sequenced by Sanger method using BigDye® Terminator v3.1 Cycle Sequencing Kit followed by analysis using a 3730xl DNA Analyzer; all equipment was from Applied Biosystems (Foster City, California). Sequence alignments were carried out using Lasergene SeqMan software. The gene sequences from reference strain FA1090 as well as parent strain were aligned with the mutant gene sequences to determine nucleotide differences.

**Drug Assay.** Samples were assayed by liquid chromatography–mass spectrometry (LC-MS/MS; Sciex 5500, Framingham, MA). The standard curves for ciprofloxacin, ceftriaxone and gepotidacin were linear, with \(r^2\) values of 0.99.
for all compounds, over ranges from 0.01 to 2.00, 0.25 to 50, and 0.01 to 25 mg/L, respectively. All standard curves and quality controls were prepared in study matrix (FB) and processed concurrently with collected samples. For ciprofloxacin, the inter assay %CV for the quality control samples at concentrations of 0.030, 0.350, 1.40 mg/L, were; 7.41%, 3.95%, and 3.17% respectively. For ceftriaxone inter assay %CV for the quality control samples at concentrations of 0.750, 8.75, 35.0 mg/L, were; 10.2%, 4.86%, and 4.22% respectively. The lower limit of quantification was 0.01 mg/L for ciprofloxacin and gepotidacin, and 0.25 mg/L for ceftriaxone.
Table 1. Susceptibility testing results and known quinolone resistance mechanisms for the five *N. gonorrhoeae* clinical isolates and one ATCC reference strain against gepotidacin, ciprofloxacin, and ceftriaxone using broth- and agar-dilution methodologies

| *N. gonorrhoeae* Isolate | Known Resistance Mechanism | Broth Microdilution MIC Using Fastidious Broth (mg/L) | Agar Dilution MIC Using Gonococcal Agar (mg/L) |
|--------------------------|----------------------------|-----------------------------------------------------|---------------------------------------------|
|                          |                            | Gepotidacin | Ciprofloxacin | Ceftriaxone | Gepotidacin | Ciprofloxacin | Ceftriaxone |
| ATCC 49226               | WT                         | 0.5        | 0.004         | 0.008       | 0.25        | 0.004         | 0.015       |
| GSK #2                  | GyrA (S91F, D95A)          | 0.25       | 2             | 0.004       | 0.5         | 2             | 0.004       |
|                         | Par C (D86N)               |            |               |             |             |               |             |
| GSK #4                  | GyrA (S91F D95G)           | 1          | 4             | 0.03        | 1           | 4             | 0.06        |
|                         | Par C (D86N)               |            |               |             |             |               |             |
| GSK #5                  | GyrA (S91F D95G)           | 1          | 4             | 0.008       | 1           | 4             | 0.015       |
|                         | Par C (D86N)               |            |               |             |             |               |             |
| GSK #7                  | GyrA (S91F D95A)           | 1          | 4             | 0.004       | 1           | 8             | 0.008       |
|                         | Par C (D86N)               |            |               |             |             |               |             |
| GSK #8                  | GyrA (S91F D95A)           | 0.5        | 2             | 0.002       | 1           | 2             | 0.002       |
|                         | Par C (D86N)               |            |               |             |             |               |             |
Table 2. Resistance frequency for the five *N. gonorrhoeae* clinical isolates grown on plates containing gepotidacin concentrations at 2.5x and 4x MIC

| *N. gonorrhoeae* Isolate | 2.5x MIC | 4x MIC |
|--------------------------|----------|--------|
| Replicate Number 1 | Replicate Number 2 | Replicate Number 3 | Replicate Number 1 | Replicate Number 2 | Replicate Number 3 |
| GSK #2 | <5.1 x 10\(^{-10}\) | <2.6 x 10\(^{-9}\) | NG | <5.1 x 10\(^{-10}\) | <2.6 x 10\(^{-9}\) | NG |
| GSK #4 | 8.0 x 10\(^{-6}\) | 9.1 x 10\(^{-5}\) | 6.0 x 10\(^{-6}\) | <1.1 x 10\(^{-8}\) | <3.1 x 10\(^{-7}\) | <7.0 x 10\(^{-9}\) |
| GSK #5 | <1.5 x 10\(^{-9}\) | <2.6 x 10\(^{-9}\) | NG | <1.5 x 10\(^{-8}\) | <2.6 x 10\(^{-9}\) | NG |
| GSK #7 | <9.5 x 10\(^{-9}\) | <1.1 x 10\(^{-8}\) | <1.2 x 10\(^{-9}\) | <9.5 x 10\(^{-9}\) | <1.1 x 10\(^{-8}\) | <1.2 x 10\(^{-9}\) |
| GSK #8 | 2.1 x 10\(^{-7}\) | 5.1 x 10\(^{-7}\) | 8.0 x 10\(^{-8}\) | <1.7 x 10\(^{-9}\) | <6.5 x 10\(^{-9}\) | 8.7 x 10\(^{-10}\) |
Figure 1. Targeted concentration time profile for gepotidacin, ceftriaxone, and ciprofloxacin in the hollow-fiber \textit{in vitro} infection model, with observed data overlaid.
Figure 2. Total and antibiotic-resistant bacterial subpopulations over time for the no-treatment, ceftriaxone 0.25 g IM, and ciprofloxacin 0.5 g PO control dosing regimens based on data for *N. gonorrhoeae* GSK #8.
Figure 3. Total and antibiotic-resistant bacterial subpopulations over time for gepotidacin dosing regimens of 0.75 to 12 g PO, representing AUC values of 16.2 to 278 mg•h/L simulated in the hollow-fiber in vitro infection model, based on data for N. gonorrhoeae GSK #8.
Figure 4. Relationship between gepotidacin total dose and median (range) change in \( \log_{10} \) CFU/mL from baseline of the gepotidacin 2x MIC subpopulation for *N. gonorrhoeae* GSK #8 on Day 7.
REFERENCES

1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M. 2015. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 Based on Systematic Review and Global Reporting. PLoS ONE 10:1-17.

2. Centers for Disease Control and Prevention. Sexually transmitted disease Surveillance, 2015. 2016. Available from: https://www.cdc.gov/std/stats15/std-surveillance-2015-printpdf. 2015.

3. Public Health England, Health Protection Report. Sexually transmitted infections and chlamydia screening in England, 2015. 2016. 10:1-27. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/534601/hpr2216_stis.pdf

4. The Kirby Institute for Infection and Immunity in Society. Annual surveillance report 2018. 2018. HIV, viral hepatitis and sexually transmissible infections in Australia. Available from: https://kirby.unsw.edu.au/report/hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-annual-surveillance

5. World Health Organization, Global health sector strategy on sexually transmitted infections 2016-2021: Implementation framework for the African region. 2017.

6. Alirol E, Wi TE, Bala M, Bazzo ML, Chen XS, Deal C, Dillon JR, Kularatne R, Heim J, Hooft van Huysduijnen R, Hook EW, Lahra MM, Lewis DA, Ndowa F, Shafer WM, Tayler L, Workowski K, Unemo M, Balasegaram M. 2017. Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines. PLoS Med 14:1-12.
7. Melendez JH, Hardick J, Barnes M, Page KR, and Gaydos CA. 2018. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates in Baltimore, Maryland, 2016: the importance of sentinel surveillance in the era of multi-drug-resistant Gonorrhea. Antibiotics 7:1-7.

8. Kidd S, Workowski A. 2015. Management of Gonorrhea in Adolescents and Adults in the United States. Clin Infect Dis 61 (Suppl8):S785-S801.

9. Gibson EG, Bax B, Chan PF, Osheroff N. 2019. Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase. ACS Infect Dis 5:570-581.

10. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND. Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940.

11. Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. CLSI document M07-A11. Clinical and Laboratory Standards Institute, Wayne, PA.

12. Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing; approved standard, 30th ed. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA. http://em100.edaptivedocs.net/Login.aspx Accessed 9, March, 2020.

13. Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, Perry CR, Raychaudhuri A, Scangarella-Oman NE, Hossain M, Dumont EF. 2018.
Gepotidacin for the treatment of uncomplicated urogenital Gonorrhea: a Phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis 67:504-512.

14. Scangarella-Oman NE, Hossain M, Dixon, PB, Ingraham K, Min S, Tiffany CA, Perry CR, Raychaudhuri A, Dumont EF, Huang J, Hook EW 3rd, Miller LA. 2018. Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Antimicrob Agents Chemother 62:e01221-18.

15. Van Der Veer Bmjw, Dukers-Muijrs Nhtm, Hoebe Cjp, Van Alphen Lb, Wolffs Pfg. 2017. P3.225 Neisseria gonorrhoeae bacterial load differs between sample sites. Sex Transm Infect 93:A177.2-A179.

16. Priest D, Ong JJ, Chow EPF, Tabrizi S, Phillips S, Bissessor M, Fairley CK, Bradshaw CS, Read TRH, Garland S, Chen M. 2017. Neisseria gonorrhoeae DNA bacterial load in men with symptomatic and asymptomatic gonococcal urethritis. Sex Transm Infect 93:478-481.

17. Chow EPF, Tabrizi SN, Phillips S, Lee D, Bradshaw CS, Chen MY, Fairley CK. 2016. Neisseria gonorrhoeae bacterial DNA load in the pharynges and saliva of men who have sex with men. J Clin Microbiol 54:2485-2490.

18. Bissessor M, Tabrizi SN, Fairley CK, Danielewski J, Whitton B, Bird S, Garland S, Chen MY. 2011. Differing Neisseria gonorrhoeae Bacterial Loads in the Pharynx and Rectum in Men Who Have Sex with Men: Implications for Gonococcal Detection, Transmission, and Control. J Clin Microbiol 49:4304-4306.
19. Cartwright CP, Stock F, Gill VJ. 1994. Improved enrichment broth for cultivation of fastidious organisms. J Clin Microbiol 32:1825-1826.

20. VanScoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest SM, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG. 2013. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 57:4134-4138.

21. VanScoy B, McCauley J, Bhavnani SM, Ellis-Grosse EJ, Ambrose PG. 2016. Relationship between fosfomycin exposure and amplification of Escherichia coli subpopulations with reduced susceptibility in a hollow-fiber infection model. Antimicrob Agents Chemother 60:5141-5145.

22. Roche Laboratories Inc. ROCEPHIN (ceftriaxone sodium) for injection. package insert. Nutley, NJ; 2004.

23. Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. Morbidity and Mortality Weekly Report 64:3.

24. Bayer HealthCare Pharmaceuticals Inc. CIPRO (ciprofloxacin hydrochloride) package insert. Whippany, NJ; 2016.

25. Echols RM, Heyd A, O’Keefe BJ, Schacht P. 1994. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary. Sex Transm Dis. 24:345-352.

26. Hossain M. Tiffany CA, McDanald M, Dumont EF. 2014. Safety and pharmacokinetics of repeat escalating oral doses of GSK2140944, a novel
topoisomerase inhibitor, abstract F-276. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC.
ACKNOWLEDGEMENTS

We thank Yinghe Li from the GlaxoSmithKline (GSK) DMPK group for her contributions to the gepotidacin PK analysis.

This work was supported by GSK. This work was also supported in whole or in part with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under other transaction authority agreement no. HHSO100201300011C. Medical writing assistance was funded by GlaxoSmithKline.